MedWatch

Analysts upgrade share price targets for Bavarian after run of good news

The Bavarian Nordic share price continues to rise on Thursday on account of new targets that predict a big upside for the stock.

Photo: Philip Davali/Ekstra Bladet, Philip Davali

After the Danish government announced plans to support Bavarian Nordic’s vaccine candidate with DKK 800m (USD 128m) in financial aid in mid-August, the company's share price has gone up by 33 percent. The company has therefore cemented its place as the C25 index's winning stock this year with returns of about 85 percent, writes Danish business daily Børsen.

On Wednesday, the state funding was followed by positive results from Bavarian Nordic's RSV vaccine candidate. On Thursday, the company was rewarded by analysts raising the share price target.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs